Chiron’s Acquisition of Powderject

doi:10.3833/pdr.v2003i37.895

Pharma Deals Review, Vol 2003, No 37 (2003)

Chiron’s Acquisition of Powderject

Business Review Editor

Abstract

Chiron entered into an agreement to acquire PowderJect Pharmaceuticals, thereby substantially expanding its product portfolio in the field of vaccines. The deal could be worth up to US$878 M to PowderJect.

Full Text: pdf

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.